HK1203928A1 - Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl]pyridine- 3 - sulfonamide 5-[5--4-(-2-)-2-)-3- - Google Patents

Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl]pyridine- 3 - sulfonamide 5-[5--4-(-2-)-2-)-3-

Info

Publication number
HK1203928A1
HK1203928A1 HK15104313.5A HK15104313A HK1203928A1 HK 1203928 A1 HK1203928 A1 HK 1203928A1 HK 15104313 A HK15104313 A HK 15104313A HK 1203928 A1 HK1203928 A1 HK 1203928A1
Authority
HK
Hong Kong
Prior art keywords
ylmethylamino
quinazolin
sulfonamide
pyridin
pyridine
Prior art date
Application number
HK15104313.5A
Other languages
English (en)
Chinese (zh)
Inventor
Jayakumar S Warrier
Navnath Dnyanoba Yadav
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1203928A1 publication Critical patent/HK1203928A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15104313.5A 2012-06-11 2015-05-06 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl]pyridine- 3 - sulfonamide 5-[5--4-(-2-)-2-)-3- HK1203928A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Publications (1)

Publication Number Publication Date
HK1203928A1 true HK1203928A1 (en) 2015-11-06

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104313.5A HK1203928A1 (en) 2012-06-11 2015-05-06 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl]pyridine- 3 - sulfonamide 5-[5--4-(-2-)-2-)-3-

Country Status (34)

Country Link
US (1) US9238666B2 (xx)
EP (1) EP2858987B1 (xx)
JP (1) JP6234450B2 (xx)
KR (1) KR102092984B1 (xx)
CN (1) CN104350048B (xx)
AR (1) AR091402A1 (xx)
AU (1) AU2013274619B2 (xx)
BR (1) BR112014030629B1 (xx)
CA (1) CA2876359C (xx)
CL (1) CL2014003361A1 (xx)
CO (1) CO7160032A2 (xx)
CY (1) CY1120432T1 (xx)
DK (1) DK2858987T3 (xx)
EA (1) EA024692B1 (xx)
ES (1) ES2675314T3 (xx)
HK (1) HK1203928A1 (xx)
HR (1) HRP20180815T8 (xx)
HU (1) HUE039210T2 (xx)
IL (1) IL236074A (xx)
LT (1) LT2858987T (xx)
MX (1) MX356699B (xx)
MY (1) MY169219A (xx)
NZ (1) NZ703632A (xx)
PE (1) PE20150228A1 (xx)
PH (1) PH12014502747B1 (xx)
PL (1) PL2858987T3 (xx)
PT (1) PT2858987T (xx)
RS (1) RS57376B1 (xx)
SG (1) SG11201408076WA (xx)
SI (1) SI2858987T1 (xx)
TN (1) TN2014000499A1 (xx)
TW (1) TWI571470B (xx)
WO (1) WO2013188254A1 (xx)
ZA (1) ZA201500161B (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970295B1 (en) * 2013-03-11 2016-12-28 Bristol-Myers Squibb Company Pyrrolopyridazines as potassium ion channel inhibitors
WO2014143606A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20180318268A1 (en) * 2015-11-19 2018-11-08 Biohaven Pharmaceutical Holding Company Ltd. Amine prodrugs of pharmaceutical compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE69940063D1 (de) 1998-07-06 2009-01-22 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
CN101084209A (zh) * 2004-12-21 2007-12-05 德福根有限公司 具有Kv4离子通道活性的化合物
LT3575288T (lt) 2009-09-03 2021-12-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2585066B1 (en) * 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
WO2014143609A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
EP2858987A1 (en) 2015-04-15
PH12014502747A1 (en) 2015-02-02
MY169219A (en) 2019-03-19
DK2858987T3 (en) 2018-07-30
JP6234450B2 (ja) 2017-11-22
BR112014030629A2 (pt) 2017-06-27
MX356699B (es) 2018-06-11
RS57376B1 (sr) 2018-08-31
IL236074A0 (en) 2015-02-01
HRP20180815T8 (hr) 2019-02-08
EA024692B1 (ru) 2016-10-31
TW201402592A (zh) 2014-01-16
SG11201408076WA (en) 2015-01-29
CN104350048A (zh) 2015-02-11
CL2014003361A1 (es) 2015-05-29
PH12014502747B1 (en) 2015-02-02
CO7160032A2 (es) 2015-01-15
CN104350048B (zh) 2016-12-07
CY1120432T1 (el) 2019-07-10
US20150175641A1 (en) 2015-06-25
ZA201500161B (en) 2017-04-26
SI2858987T1 (en) 2018-06-29
PT2858987T (pt) 2018-07-04
BR112014030629B1 (pt) 2021-12-21
HUE039210T2 (hu) 2018-12-28
NZ703632A (en) 2016-01-29
ES2675314T3 (es) 2018-07-10
KR102092984B1 (ko) 2020-03-24
AU2013274619A1 (en) 2015-01-29
HRP20180815T1 (hr) 2018-06-29
CA2876359C (en) 2020-01-21
AU2013274619B2 (en) 2017-09-28
PL2858987T3 (pl) 2018-08-31
CA2876359A1 (en) 2013-12-19
AR091402A1 (es) 2015-02-04
WO2013188254A1 (en) 2013-12-19
MX2014014525A (es) 2015-02-24
TN2014000499A1 (en) 2016-03-30
TWI571470B (zh) 2017-02-21
EP2858987B1 (en) 2018-04-25
PE20150228A1 (es) 2015-02-19
IL236074A (en) 2016-08-31
US9238666B2 (en) 2016-01-19
KR20150023667A (ko) 2015-03-05
LT2858987T (lt) 2018-07-10
JP2015521598A (ja) 2015-07-30
EA201492256A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
HK1212701A1 (zh) 恩雜魯胺製劑
IL233861B (en) A type of glyphosate resistant genes
EP2931284A4 (en) BACE INHIBITORS OF IMINOTHIADIAZINOXIDES
EP2803053A4 (en) AUTOMATED RECOGNITION OF GAME PREFERENCES
AP4029A (en) Inhibitors of beta-secretase
EP2934534A4 (en) C5-SPIRO-IMINOTHIADIAZINDIOXIDES AS BACE INHIBITORS
EP2814487A4 (en) BENDAMUSTIN FORMULATIONS
PL2819982T3 (pl) Proleki witaminy k
EP2934149A4 (en) C6-AZASPIRO-IMINOTHIADIAZINDIOXIDES AS BACE INHIBITORS
HRP20180815T1 (hr) Prolijekovi fosforamidne kiseline 5-[5-fenil-4-(piridin-2-ilmetilamino)hinazolin-2-il]piridin-3-sulfonamida
ZA201504442B (en) Regulation of gene expression
HK1209046A1 (en) Manufacture of degarelix
IL236963A0 (en) beta-secretase inhibitors
GB201206455D0 (en) Gene expression
HK1214601A1 (zh) 用於製造 -標記物的新型雙-銥-配合物
EP2738254A4 (en) PHOSPHATIDE ACID PHOSPHATASE GENE
GB201116822D0 (en) Jack of all trades
GB201204590D0 (en) Prodrugs of thiazolamine compounds
GB201204587D0 (en) Prodrugs of guanidine compounds
GB201204589D0 (en) Prodrugs of guanidine compounds